Link: Pharmaceutical Business Review
Swiss biotech firm Basilea Pharmaceutica has received positive results for its first comparative phase III trial with ceftobiprole as a treatment for MRSA. Ceftobiprole showed a high cure rate and was safe and well tolerated. This first-in-class anti-MRSA broad-spectrum cephalosporin is being developed in partnership with Cilag AG International, a Johnson & Johnson company.
